Heat and 4-hydroperoxy-ifosfamide-induced apoptosis in B cell precursor leukaemias

International Journal of Hyperthermia

Volumn 19, Issue 4, 2003, Pages 444-460

  Mauz Korholz C ^a   Dietzsch, S ^a   Banning, U ^a   Trobs R B ^a   Korholz D ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Acute lymphoblastic leukaemia; 4 Hydroperoxy ifosfamide; Apoptosis; Thermochemotherapy

Indexed keywords

4 HYDROPEROXYIFOSFAMIDE; CASPASE 3; CASPASE 8; CASPASE 9; INTERLEUKIN 1BETA CONVERTING ENZYME;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; BLAST CELL CRISIS; CANCER RECURRENCE; CHILD; CLINICAL ARTICLE; CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME KINETICS; FEMALE; HUMAN; HUMAN CELL; HYPERTHERMIA; INFANT; LEUKEMIA CELL LINE; MALE; MOLECULAR DYNAMICS; STEM CELL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CASPASES; CELL LINE, TUMOR; HEAT; HUMANS; IFOSFAMIDE; INTRACELLULAR MEMBRANES; LEUKEMIA, B-CELL; PRECANCEROUS CONDITIONS;

EID: 0038421014     PISSN: 02656736     EISSN: None     Source Type: Journal    
DOI: 10.1080/0265673031000063864     Document Type: Article

References (47)

1. Schrappe M, Reiter A, Zimmermann M, Harbott J, Ludwig WD, Henze G, Gadner H, Odenwald E, Riehm H. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia 2000; 14: 2205-22.
2. Harms DO, Janka-Schaub GE. Co-operative study group for childhood acute lymphoblastic leukemia (COALL): Long-term follow-up of trials 82, 85, 89 and 92. Leukemia 2000; 14: 2234-9.
3. Pui CH. Acute lymphoblastic leukemia in children. Curr Opin Oncol 2000; 12: 3-12.
4. Arico M, Valsecchi MG, Camitta B, Schrappe M, Chessells J, Baruchel A, Gaynon P, Silverman L, Janka-Schaub G, Kamps W, Pui CH, Masera G. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med 2000; 342: 998-1006.
5. Bührer C, Hartmann R, Fengler R, Rath B, Schrappe M, Janka-Schaub G, Henze G. Peripheral blast counts at diagnosis of late isolated bone marrow relapse for childhood acute lymphoblastic leukemia predict response to chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study group. J Clin Oncol 1996; 14: 2812-7.
6. Seeger K, Kreuzer K-A, Lass U, Taube T, Buchwald D, Eckert C, Körner G, Schmidt CA, Henze G. Molecular quantification of response to therapy and remission status in TEL-AML1-positive childhood ALL by real-time reverse transcription polymerase chain reaction. Cancer Res 2001; 61: 2517-22.
7. Niethammer D, Klingebiel T, Ebell W, Henze G, Paolucci P, Riehm H. Which children do benefit from bone marrow transplant? The EBMT paediatric diseases working party. Bone Marrow Transplant 1996; 18 (suppl 2): 43-6.
8. Klumper E, Pieters R, Veerman AJ, Huismans DR, Loonen AH, Hahlen K, Kaspers GJ, Van Wering G. In vitro cellular drug resistance in children with relapsed/refractory lymphoblastic leukemia. Blood 1995; 86: 3861-8.
9. Kutz ME, Mulkerin DL, Wiedemann GJ, Katschinski DM, Robins HI. In vitro studies of the hyperthermic enhancement of activated ifosfamide (4-hydroperoxy-ifosfamide) and glucose isophosphoramide mustard. Cancer Chemother Pharmacol 1997; 40: 167-71.
10. Robins HI, Neville AJ, Cohen JD. Whole body hyperthermia: Biological, and clinical aspects. In: Gautherie M, ed. Clinical Thermology. Berlin, Heidelberg: Springer-Verlag, 1992; 64.
11. Falk MH, Issels RD. Hyperthermia in oncology. Int J Hyperthermia 2001; 17: 1-18.
12. Wessalowski R, Kruck H, Pape H, Kahn T, Willers R, Göbel U. Hyperthermia for the treatment of patients with malignant germ cell tumors: A phase I/II study in ten children and adolescents with recurrent or refractory tumors. Cancer 1998; 82: 793-800.
13. Wessalowski R, Willnow U, Jürgens H, Dehnen H, Göbel U. Total body hyperthermia in combination with etoposide and melphalan in a child with acute myelomonocytic leukemia. Med Pediatr Oncol 1994; 22: 61-5.
14. Wiedemann GJ, D'Oleire F, Knop E, Eleftheriadis S, Bucsky P, Feddersen S, Klouche M, Geisler J. Ifosfamide and carboplatin combined with 41.8 degrees C whole-body hyperthermia in patients with refractory sarcoma and malignant teratoma. Cancer Res 1994; 15: 5346-50.
15. Wendtner C, Abdel-Rahman S, Baumert J, Falk MH, Krych M, Santl M, Hiddemann W, Isrels RD. Treatment of primary, recurrent or inadequately resected high-risk-soft-tissue sarcomas (STS) of adults: Results of a phase II pilot study (RHT-95) of neoadjuvant chemotherapy combined with regional hyperthermia. Eur J Cancer 2001; 37: 1609-16.
16. Bakhshandeh A, Bruns I, Eberhardt K, Wiedemann GJ. Chemotherapy in combination with whole-body hyperthermia in advanced malignant pleural mesothelioma. Dtsch Med Wochenschr 2000; 17: 317-9.
17. Schwartz PS, Waxman DJ. Cyclophosphamide induces caspase-9-dependent apoptosis in 9L tumor cells. Mol Pharmacol 2001; 60: 1268-79.
18. Takasu T, Lyons JC, Park HJ, Song CW. Apoptosis and perturbation of cell cycle progression in acidic environment after hyperthermia. Cancer Res 1998; 58: 2504-8.
19. Katschinski DM, Robins HI, Schad M, Frede S, Fandrey J. Role of tumor necrosis factor a in hyperthermia-induced apoptosis of human leukemia cells. Cancer Res 1999; 59: 3404-10.
20. Gorman AM, Heavey B, Creagh E, Cotter TG, Samali A. Antioxidant-mediated inhibition of the heat shock response leads to apoptosis. FEBS Lett 1999; 445: 98-102.
21. Falcieri E, Luchetti F, Burattini S, Canonico B, Santi S, Papa S. Lineage-related sensitivity to apoptosis in human tumor cells undergoing hyperthermia. Histochem Cell Biol 2000; 113: 135-44.
22. Okamoto K, Shinoura N, Egawa N, Asai A, Kirino T, Shibasaki F, Slinfara N. Adenovirus-mediated transfer of p53 augments hyperthermia-induced apoptosis in U251 gliomas cells. Int J Radiat Oncol Biol Phys 2001; 50: 525-6.
23. Hermisson M, Wagenknecht B, Wolburg H, Glaser T, Dichgans J, Weller M. Sensitization to CD95 ligand-induced apoptosis in human glioma cells by hyperthermia involves enhanced cytochrome c release. Oncogene 2000; 19: 2338-45.
24. Arends J. Effects of a combined thermochemotherapy on markers of apoptosis, differentiation and adhesion in the human mammary carcinoma MX-1. Ann Anat 2000; 182: 339-47.
25. Körholz D, Banning U, Bönig H, Grewe M, Schneider M, Mauz-Körholz C, Klein-Velane A, Krutmann J, Burdach S. The role of interleukin 10 (IL-10) in IL-15-mediated T cell responses. Blood 1997; 90: 4513-21.
26. Barry MA, Behnke CA, Eastman A. Activation of programmed cell death (apoptosis) by cisplatin, other anticancer drugs, toxins and hyperthermia. Biochem Pharmacol 1990: 40: 2353-62.
27. Miller TM, Moulder KL, Knudson CM, Creedon DJ, Deshmukh M, Korsmeyer SJ, Johnson EM. Bax deletion further orders the cell death pathway in cerebellar granule cells and suggests a caspase-independent pathway to cell death. J Cell Biol 1997; 139: 205-17.
28. Xiang J, Chao DT, Korsmeyer SJ. Bax-induced cell death may not require interleukin 1-beta-converting enzyme-like proteases. Proc Natl Acad Sci USA 1996; 93: 14559-63.
29. Stahnke K, Fulda S, Friesen C, Strauß G, Debatin KM. Activation of apoptosis pathways in peripheral blood lymphocytes by in vivo chemotherapy. Blood 2001; 98: 3066-73.
30. Herr I, Debatin KM. Cellular stress response and apoptosis and cancer therapy. Blood 2001; 98: 2603-14.
31. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvemet of MACH, a novel MORT1/FADD-interacting protein in Fas/APO-1 and TNF receptor-induced cell death. Cell 1996; 85: 803-15.
32. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 1997; 91: 479-89.
33. Cohen GM. Caspases: The executioners of apoptosis. Biochem J 1997; 326: 1-16.
34. Katschinski DM, Boos K, Schindler SG, Fandrey J. Pivotal role of ractive oxygen species as intracellular mediators of hyperthermia-induced apoptosis. J Biol Chem 2000; 275: 21094-8.
35. Kobayashi D, Watanabe N, Yamauchi N, Okamoto T, Tsuji N, Sasaki H, Sato T, Niitsuu Y. Heat-induced apoptosis via caspase-3 activation in tumour cells carrying mutant p53. Int J Hyperthermia 2000; 16: 471-80.
36. Friesen C, Herr I, Krammer PH, Debatin K.-M. Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med 1996; 2: 574-7.
37. Becker R, Ritter A, Eichhorn U, Lips J, Bertram B, Wiesser M, Zdzienicka MZ, Kaina B. Induction of DNA breaks and apoptosis in crosslink-hypersensitive V79 cells by the cytostatic drug beta-D-glycosyl-ifosfamide mustard. Br J Cancer 2002; 86: 130-5.
38. Karle P, Renner M, Salmons B, Günzburg WH. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide. Cancer Gene Ther 2001; 8: 220-30.
39. Poyet JL, Srinivasula SM, Tnani M, Razmara M, Fernandes-Alnemri T, Alnemri ES. Idetification of Ipaf, a human caspase-1-activating protein related to Apaf-1. J Biol Chem 2001; 276: 28309-13.
40. Geddes BJ, Wang L, Huang WJ, Lavelee M, Manji GA, Brown M, Jurman M, Cao J, Morgenstern J, Merriam S, Glucksmann MA, Distefano PS, Bertin J. Human CARD12 is a novel CED4/Apaf-1 family member that induces apoptosis. Biochem Biophys Res Commun 2001; 77-82.
41. Ueki T, Takeuchi T, Nishimatsu H, Kajiwara T, Moriyama N, Narita Y, Kawabe K, Ueki K, Kistamura T. Silencing of the caspase-1 gene occurs in murine and human renal cancer cells and causes solid tumor growth in vivo. Int J Cancer 2001; 91: 673-93
42. Muguruma K, Nakata B, Yanagawa K, Nitta A, Yashiro M, Onoda N, Mirakawa K Caspase-1 activity as a possible predictor of apoptosis induced by cisplatin in gastric cancer cells. Int J Mol Med 2000; 6: 553-7.
43. Hisahara S, Takano R, Shoji S, Okano H, Miura M. Role of caspase-1 subfamily in cytotoxic cytokine-induced oligodendrocyte cell death. J Neural Transm Suppl 2000; 58: 135-42.
44. Hermisson M, Weller M. Hyperthermia enhanced chemosensitivity of human malignant glioma cells. Anticancer Res 2000; 20: 1819-1823.
45. Othman T, Goto S, Lee J.-B, Taimura A, Matsumoto T, Kosaka M. Hyperthermic enhancement of the apoptotic and antiproliferative activities of paclitaxel. Pharmacology 2001; 62: 208-12.
46. Sarosy G. Ifosfamide-pharmacologic overview. Semin Oncol 1989; 16 (suppl 3): 2-8.
47. Schmid H, Von Schenck U, Hartmann R, Borgmann A, Henze G. Allogeneic BMT vs. chemotherapy in late bone marrow relapsed childhood non-T/non-B ALL: Results of BFM ALL relapse studies. BFM relapse study group. Bone Marrow Transplant 1996; 18 (suppl 2): 28-30.